A new study uses shopping receipts to show how appetite changes from Ozempic and Wegovy affect grocery and restaurant ...

As Novo Nordisk’s weight-loss pill Wegovy (semaglutide) readies for a launch in the United States early January, it will be a ...

Tradipitant is a neurokinin-1 receptor antagonist licensed by Vanda from Eli Lilly and Company. ・The drug is also being developed to treat gastroparesis. ・Last month, Vanda reported positive topline ...

People covered by Obamacare and Medicaid may see health care costs rise, but for people on Medicare, Biden-era negotiated ...

Major stock indexes ended higher for a fourth straight session Tuesday, with the S&P 500 setting a fresh closing record, ...

The Danish drugmaker will start selling a pill version of its Wegovy weight-loss medicine in January, after [securing ...

As GLP-1 weight-loss drugs become more common, their effects may be reshaping everyday food choices in ways that extend far beyond individual health. When people in the United States begin using ...

Packaged food makers and fast-food restaurants may be forced to overhaul more of their products next year as newly approved, appetite-suppressing GLP-1 pills become available in January, analysts say.

U.S. regulators this week gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study. And through the first nine months of 2025, Zepbound generated $9.3 billion ...

The American Academy of Pediatrics sued the U.S. Department of Health and Human Services on Wednesday, seeking to block ...

The Food and Drug Administration has approved Wegovy in pill form. Dr. Jon LaPook has the story of one man, Dr. Chris Mertens ...